R 1549

Drug Profile

R 1549

Alternative Names: Monoclonal antibody HMFG1 yttrium 90 labelled; Pemtumomab; R1549; Theragyn; Yttrium 90 labelled monoclonal antibody HMFG1

Latest Information Update: 20 Sep 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research UK
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastric cancer; Ovarian cancer

Most Recent Events

  • 20 Sep 2004 Discontinued - Phase-II for Gastric cancer in United Kingdom (Intraperitoneal)
  • 20 Sep 2004 Discontinued - Phase-III for Ovarian cancer in Australia (Intraperitoneal)
  • 20 Sep 2004 Discontinued - Phase-III for Ovarian cancer in Austria (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top